A carregar...
Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles
The commercially available rebamipide ophthalmic suspension (CA-REB) was approved for clinical use in patients with dry eye; however, the residence time on the ocular surface for the traditional formulations is short, since the drug is removed from the ocular surface through the nasolacrimal duct. I...
Na minha lista:
| Publicado no: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7076486/ https://ncbi.nlm.nih.gov/pubmed/32075200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12020155 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|